Prediction of Global Functional Outcome and Post-Concussive Symptoms after Mild Traumatic Brain Injury: External Validation of Prognostic Models in the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) Study

Ana Mikolić,1 Suzanne Polinder,1 Ewout W. Steyerberg,1,2 Isabel R.A. Retel Helmrich,1 Joseph T. Giacino,3,4 Andrew I. R. Maas,5 Joukje van der Naalt,6 Daphne C. Voormolen,5 Nicole von Steinbüchel,7 Lindsay Wilson,8 Hester F. Lingsma,1 David van Klaveren1,9; and the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) Study Participants and Investigators*

Abstract

The majority of traumatic brain injuries (TBIs) are categorized as mild, according to a baseline Glasgow Coma Scale (GCS) score of 13–15. Prognostic models that were developed to predict functional outcome and persistent post-concussive symptoms (PPCS) after mild TBI have rarely been externally validated. We aimed to externally validate models predicting 3–12-month Glasgow Outcome Scale Extended (GOSE) or PPCS in adults with mild TBI. We analyzed data from the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) project, which included 2862 adults with mild TBI, with 6-month GOSE available for 2374 and Rivermead Post-Concussion Symptoms Questionnaire (RPQ) results available for 1605 participants. Model performance was evaluated based on calibration (graphically and characterized by slope and intercept) and discrimination (C-index). We validated five published models for 6-month GOSE and three for 6-month PPCS scores. The models used different cutoffs for outcome and some included symptoms measured 2 weeks post-injury. Discriminative ability varied substantially (C-index between 0.58 and 0.79). The models developed in the Corticosteroid Randomisation After Significant Head Injury (CRASH) trial for prediction of GOSE <5 discriminated best (C-index 0.78 and 0.79), but were poorly calibrated. The best performing models for PPCS included 2-week symptoms (C-index 0.75 and 0.76). In conclusion, none of the prognostic models for early prediction of GOSE and PPCS has both good calibration and discrimination in persons with mild TBI. In future studies, prognostic models should be tailored to the population with mild TBI, predicting relevant end-points based on readily available predictors.

Keywords: external validation; Glasgow Outcome Scale Extended; mild traumatic brain injury; post-concussive symptoms; prognostic model
Introduction

Traumatic brain injury (TBI) is a major health concern with >50,000,000 new cases reported globally every year.\(^1\)\(^2\) Approximately 70–90% of patients with TBI present with a Glasgow Coma Score (GCS) of 13–15, which falls in the mild TBI category.\(^3\) Although the majority of these patients recover shortly after the incident, a notable percentage continue to have persistent complaints. These complaints can interfere with daily life and social and work activities,\(^4\)\(^5\) and ~50% of persons with mild TBI do not return to their pre-injury level of functioning 6 months after injury.\(^6\)\(^7\)\(^8\)

The most prominent post-injury disturbances are cognitive, emotional, somatic, and behavioral symptoms, often referred to as post-concussive symptoms,\(^9\) or if the sequela of symptoms persist over time, post-concussion syndrome (PCS). The concept of PCS has been questioned in recent years,\(^10\) and, therefore, some authors refer to the multiple concurrent post-concussive symptoms several months after TBI as persistent post-concussive/post-concussion symptoms (PPCS).\(^11\)\(^12\)\(^13\)\(^14\) The prevalence of 6-month PPCS after mild TBI varies substantially among studies, partly because of differences in diagnostic criteria, and is typically between 10% and 40% in civilian samples presenting to hospitals.\(^4\)\(^15\)\(^16\)\(^17\)\(^18\)

Considering the high percentage of functionally impaired persons with mild TBI, the economic burden of prolonged treatment and decreased productivity,\(^9\) it is important to promptly identify persons who are at high risk of long-term consequences. Therefore, a well-performing prognostic model for outcome prediction after mild TBI is important to assist patients and health-care providers in making well-informed treatment decisions. Before implementation of a model for decision making in clinical practice can be considered, it is crucial to assess its performance in an external validation study. In recent years, there have been initiatives toward external validation of prognostic models for mild TBI,\(^6\)\(^20\) but validation studies are still scarce. The Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) project provides an excellent opportunity for external validation of existing models in a large prospective cohort of contemporary TBI patients from 18 countries across Europe, and Israel.\(^21\)

The aim of this study was to examine the performance of existing models for prediction of outcome following mild TBI. We searched for published predictors and prognostic models for functional outcome (Glasgow Outcome Scale Extended [GOSE]) and PPCS for mild TBI and validated selected prognostic models using the CENTER-TBI database.

Methods

Study population

The study population consisted of patients from the prospective longitudinal observational CENTER-TBI study (Core data, version 2.0). Data were collected from December 2014 to December 2017 in 58 centers across Europe and Israel. Ethical approval was granted for each recruiting site and informed consent was obtained for all patients by the patients and/or their legal representative/nest of kin. Institutions participating in CENTER-TBI were mainly referral centers for neurotrauma. Patients who were not seen in study hospitals were not included. Inclusion criteria for the core study were a clinical diagnosis of TBI, presentation within 24 h after injury, and an indication for computed tomography (CT) scanning. The exclusion criterion was any severe pre-existing neurological disorder that could confound outcome assessments.\(^27\) The core data set included three strata that were differentiated according to care path: patients seen in the emergency room (ER); patients primarily admitted to the intensive care unit (ICU), and patients primarily admitted to the hospital ward (non-ICU).

For this study, 2862 (≥ 16 years of age) adults with mild TBI, as defined by a baseline GCS of 13–15, were included; 2374 of the records had information on 6-month GOSE, and 1605 had information on some or all 6-month Rivermead Postconcussion Symptoms Questionnaire (RPQ)\(^22\) items, measuring PPCS.

Measurements

Predictors. Sociodemographic, pre-injury and injury characteristics were based on information in hospital charts. Imaging, blood sampling, and neurological assessment were performed in the ER. Post-concussive and psychological symptoms were assessed at 2–3 weeks post-injury (range 10–27 days) in patients admitted to the ER, and in some centers (participating in an additional imaging sub-study), also in patients admitted to a hospital ward other than the ICU. The following instruments were used: RPQ for post-concussive symptoms, PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders, Fifth edition (DSM-5) (PCL-5)\(^23\) to screen for post-traumatic stress disorder (PTSD), Patient Health Questionnaire (PHQ-9)\(^24\) to screen for depression, and Generalized Anxiety Disorder (GAD-7)\(^25\) to screen for anxiety.

Outcome. The GOSE is widely used as a primary outcome measure in TBI studies.\(^26\) The GOSE provides eight categories of outcome: dead (1), vegetative state (2), lower severe disability (3), upper severe disability (4), lower moderate disability (5), upper moderate disability (6), lower good recovery (7), and upper good recovery (8). The highest score (8) represents a complete return to a pre-injury level of functioning.\(^27\) The GOSE was assessed 6 months post-injury, and when outside the time window (range 5–8 months), it was imputed based on GOSE measurements at other time points (~30%, described in Steyerberg and coworkers).\(^2\) The RPQ is the most frequently employed self-reported symptom inventory measuring PPCS.\(^28\) The RPQ consists of 16 cognitive, somatic, and emotional symptoms that can be assessed from ‘not experienced at all’ (0) to ‘severe problem’ (4), and it was administered 6 months post-injury.

The self-report instruments were administered in 18 languages. Prior to the data collection, instruments existing only in English were translated and linguistically validated in the respective languages according to the guidelines of Acquaro.\(^29\) The linguistic validation procedure consisted of multiple steps, including forward translation, cognitive debriefing, backward translation, harmonization, and finalization of translated versions. A manuscript dedicated to the linguistic validations is currently in preparation. Psychometric properties of the instruments have been investigated using criteria of the classical test and item response theory (other publications in preparation).\(^30\)\(^31\)\(^32\)

Selection of prognostic models

Eligible prognostic models were selected based on a rapid review with pre-defined search strategy and pre-defined inclusion criteria. Prognostic models and predictors of GOSE or PPCS were identified by a search in MEDLINE,\(^33\) Embase, and the Cochrane Library, which included studies published until May 2019 (Table S1), and reference lists of systematic reviews.\(^34\)\(^35\) Prognostic models were included if they were developed to predict GOSE or PPCS at 3–12 months post-injury in patients with GCS 13–15 at baseline. Models that were developed in populations that included other TBI severities were also selected if at least a proportion of patients had a GCS between 13 and 15. Moreover, models had to fulfill at least one of the following quality criteria to be considered eligible: (1) large sample size (n > 500), (2) > 10
outcome events for each candidate predictor considered and (3) the use of shrinkage and/or some form of internal validation. We extracted predictors of outcome from eligible models and from all studies that explored prediction of 3–12-month GOSE and PPCS in persons with mild TBI.

Statistical analyses

The external validity of the models was assessed with measures of calibration and discrimination. Calibration is the agreement between predicted and observed outcome values and was measured by the calibration intercept and the calibration slope, and visualized by a calibration plot. The calibration intercept expresses calibration-in-the-large: if the outcomes are systematically underestimated (intercept <0) or overestimated (intercept >0), and the calibration slope indicates if the strength of the associations between predictors and outcomes is underestimated (slope >1; “underfit”) or overestimated (slope <1; “overfit”). A calibration plot graphically compares mean observed with mean predicted outcomes. In a perfect scenario, the calibration intercept and slope would be 0 and 1, respectively, and combinations of predicted and observed outcomes would be on the 45 degree line. Discrimination refers to the ability to classify patients with a poor versus a good outcome based on a prognostic model, and was assessed by the area under the operator receiver characteristic curve (AUC), which is equal to the concordance (C) index in logistic regression models. The AUC or C-index ranges between 0.50 (no discrimination, equal to chance) and 1.0 (perfect discrimination).

The C-index obtained in validation studies is influenced by differences in both the regression coefficients (slope) and the case-mix heterogeneity. To disentangle their influence on the discriminative ability of logistical regression models, we used the model-based concordance (mbc), which is only influenced by differences in case-mix heterogeneity.

All models were validated using patients with GCS 13–15 with all information on the relevant predictors available in the CENTER-TBI data set (“complete case analysis”). When predictors were not registered in CENTER- TBI, and therefore were completely unavailable, their predictor effect was set to 0, and only discrimination and calibration slope were assessed. As a sensitivity analysis, models were also validated in all patients with GCS 13–15, using imputation to complete missing data in predictors (“imputation analysis” in one complete data set).

All analyses were performed in R (3.5.3, R Foundation for Statistical Computing. Vienna, Austria, 2019) using the rms package for model validation and the mice package for imputation (‘’imputation analysis’’ in one complete data set).

Results

Model selection

Based on the literature search criteria (Table S1), 417 abstracts were screened. Based on the full-text screen, 43 articles described predictors of 3–12-month PPCS (n = 29), GOSE (n = 11), or both (n = 3), and 5 articles presented prognostic models for prediction of GOSE (n = 9) and PPCS (n = 3) (Tables 1, S2, and S3). The most frequent predictors in prognostic models were age, GCS, and extracranial injuries, and alcohol intoxication (Table 1). Other frequent predictors of outcome were: sex/gender, education, pre-injury mental health, neuroimaging markers, cause of injury, symptoms and post-injury symptoms (Tables 1, S4, and S5).

We validated five models predicting GOSE and three models predicting PPCS (Tables 2 and 3). An additional three models were deemed unsuitable for validation because >70% of predictor variables were not available (CT and Combined Nijmegen model or because the model equation was not available (emergency department [ED] UPFRONT model).

Eligible models predicting GOSE

Models for predicting 6-month GOSE were the Basic and CT models from the Corticosteroid Randomisation After Significant Head Injury (CRASH) trial, clinical models for mild TBI and isolated TBI from the Nijmegen Radboud University Brain Injury Cohort Study (RUBICS) study, and the ED+ model from the UPFRONT study (Table 2). All models predicted dichotomized GOSE, but with different defined end-points: severe disability or death (GOSE <5), disability or death (GOSE <7), or complete/upper good recovery (GOSE = 8), respectively (Table 2). They contained different predictors, but all models included a measure of injury severity (GCS, Injury Severity Score [ISS], or major extracranial injury), and most models also included age and alcohol intoxication. In addition to admission characteristics, the UPFRONT model included 2-week symptoms (Table 2), which were assessed with different instruments than in the CENTER-TBI study (and therefore rescaled in validation). The predictors neck pain at the ER and coping styles from the UPFRONT model were not assessed in the CENTER-TBI study. The CRASH models were developed in an adult population with GCS 3–14, which partly includes mild TBI. In our study, they were validated in adults with GCS 13–15 and GCS 13–14. Other models were developed only in the population with GCS 13–15. The UPFRONT model was developed in patients with loss of consciousness (LOC) <30 min and post-traumatic amnesia (PTA) <24 h, and no major psychiatric disorders (Table 2). These inclusion criteria were not used in our validation, but were applicable to the majority of the validation population and therefore were not expected to impact the results.

Eligible models predicting PPCS

Models predicting 6-month PPCS were developed in the Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) pilot study, UPFRONT, and Nijmegen studies (Table 3). The endpoint was differently defined or measured by different instruments (Table 3). In the TRACK-TBI pilot study, PPCS were assessed with the RPQ and dichotomized according to International Classification of Diseases (ICD) criteria for PCS; that is, a score ≥2 on at least three of the following symptoms: headache, dizziness, fatigue, irritability, sleep disturbances, poor concentration, forgetfulness, poor memory, frustration, or depression. In the UPFRONT study, dichotomization of PCS was done in a similar way, but measured using the Head Injury Severity Checklist (HISC). The Nijmegen study defined high PPCS as a score ≥2 on 13 out of all 16 RPQ items. The TRACK-TBI Pilot model only included admission characteristics as predictors, whereas the other models also included symptoms measured ~2 weeks post-injury (Table 3). These symptoms were assessed by different instruments (Table S6). In addition, there were some differences between development and validation studies in the definition and measurement of pre-injury mental and physical health, headache, and nausea (Table S6). The TRACK-TBI Pilot study excluded patients with major psychiatric, neurological, or life-threatening diseases; UPFRONT included patients who sustained LOC or PTA, and without substance addiction; and Nijmegen included patients age 18–60 and LOC <30 min (Table 3). The validation population was not
restricted based on age, psychiatric disorder, LOC, or PTA. Substance addiction and LOC >30 min were reported for only a small number of patients in the validation population. As sensitivity analyses, the validation population for the UPFRONT model was restricted to sustained LOC and/or PTA, and the validation population for the Nijmegen model was restricted to age group 18–60 (Table S9).

CENTER-TBI data

In total, 2862 adults with mild TBI were included in CENTER-TBI. The majority were male (64%) and approximately half were admitted to a non-ICU hospital ward (47%). The mean age was 53 years (interquartile range [IQR] 33–68), and the mean years of education was 13 (11–16). The majority of patients had a GCS of 15 (71%). More than a quarter had a major extracranial injury (27%) and almost half had CT abnormalities (45%) (Table S7).

Subsamples without available 6-month outcomes did not differ from the overall cohort in the majority of baseline characteristics, but patients with completed 6-month RPQ were somewhat more educated, and had more CT abnormalities at baseline, a higher proportion of PTA and LOC, and a slightly lower percentage of psychiatric disorders (Table S7).

Sample with both 2–3 week symptoms and 6-month outcomes differed from the total cohort: patients were mostly discharged after ER and had a median age of 51 years (35–63), and there was a higher proportion of females, more patients with GCS 15, and a smaller proportion of patients with major extracranial injuries and with CT abnormalities (Table S7).

---

Table 1. Predictors of Glasgow Outcome Scale Extended (GOSE) and Persistent Post-Concussive Symptoms (PPCS) from the Models Validated in the CENTER-TBI Data

<table>
<thead>
<tr>
<th>Predictor</th>
<th>GOSE</th>
<th>PPCS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CRASH</td>
<td>Nijmegen, RUBICS</td>
</tr>
<tr>
<td></td>
<td>Basic</td>
<td>Clinical all</td>
</tr>
<tr>
<td>Pre-injury and sociodemographic characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>XX</td>
<td>XX</td>
</tr>
<tr>
<td>Sex or gender</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Education</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Country income</td>
<td>XX</td>
<td></td>
</tr>
<tr>
<td>Mental health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous TBI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache/migraine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seizures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injury and peri-injury characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCS</td>
<td>XX</td>
<td>XX</td>
</tr>
<tr>
<td>Abnormal pupillary response</td>
<td>XX</td>
<td>XX</td>
</tr>
<tr>
<td>Injury severity</td>
<td>XX</td>
<td></td>
</tr>
<tr>
<td>Hypotension</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>CT abnormalitiesa</td>
<td>XX</td>
<td>X</td>
</tr>
<tr>
<td>Cause of injury</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Extracranial injury</td>
<td>XX</td>
<td>XX</td>
</tr>
<tr>
<td>Facial fractures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTA</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>LOC</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Time from injury</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol intoxication</td>
<td>XX</td>
<td>XX</td>
</tr>
<tr>
<td>Anticoagulants</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Neck pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early symptomsb</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anxiety</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-concussive symptoms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-traumatic stress</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coping styles</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Self-efficacy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Hemorrhagic contusion, petechial hemorrhage, ventricle and cisterns obliteration, subarachnoid hemorrhage, mid-line shift, non-evacuated hematoma
*Headache, nausea, dizziness

XX, final model; X, candidate predictor; CENTER-TBI, Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury; CRASH, Corticosteroid Randomisation After Significant Head Injury; CT, computed tomography; ED, emergency department; GCS, Glasgow Coma Score; LOC, loss of consciousness; PTA, post-traumatic amnesia; RUBICS, Radboud University Brain Injury Cohort Study; TBI, traumatic brain injury; TRACK-TBI, Transforming Research and Clinical Knowledge in TBI; UPFRONT.
Table 2. Models for Predicting Glasgow Outcome Scale Extended (GOSE) Validated in the CENTER-TBI Data

<table>
<thead>
<tr>
<th>Study</th>
<th>Model</th>
<th>Population; Setting</th>
<th>Outcome</th>
<th>Predictors</th>
<th>Reported performance (AUC)</th>
</tr>
</thead>
</table>
| CRASH, 2008 | Basic model | Adult; GCS 3-14                                           | GOS <4 (GOSE <5) at 6 months | • Age (after 40 years)  
• GCS  
• Pupillary reactivity  
• Extradural injury  
Basic model plus  
• Petechial hemorrhage  
• Obliteration of third ventricle and cisterns  
• Subarachnoid hemorrhage  
• Mid-line shift  
• Non-evacuated hematoma  
• Injury Severity Score Total  
• Alcohol intoxication | 0.81a  
0.83a |
|             | CT model |                                           |                     |                                                                             |                            |
| Nijmegen-RUBICS, 2010 | Clinical model | Adult; GCS 13-15 Neurological/surgical consultation; Level 1 trauma center, the Netherlands, 1998-2005 GCS; 13-15 No polytrauma (isolated TBI) | GOSE <7 at 6 months | • Age  
• Injury Severity Score Total  
• Alcohol intoxication | 0.71  
0.69 |
| UPFRONT, 2017 | ED+ model | Adult; GCS 13-15 LOC <30 min; PTA <24h, no major psychiatric disorder; Three level-1 trauma centers, the Netherlands, 2013-2015 | GOSE = 8 at 6 months | • Age  
• Injury Severity Score-Head  
• Alcohol intoxication  
• Education  
• Mental health history  
• Alcohol intoxication  
• Neck pain  
• GCS  
• PTA duration  
• Depression (2 weeks)  
• Anxiety (2 weeks)  
• Complaints (2 weeks)  
• Passive coping style  
• Avoidant coping style | 0.77b |

aFor high-income countries  
bAfter internal validation  
AUC, area under the curve; C, concordance; CENTER-TBI, Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury; CRASH, Corticosteroid Randomisation After Significant Head Injury; CT, computed tomography; ED, emergency department; GCS, Glasgow Coma Score; LOC, loss of consciousness; PTA, post-traumatic amnesia; RUBICS, Radboud University Brain Injury Cohort Study; UPFRONT.

More than 70% of persons achieved good recovery (GOSE ≥7), with 49% of persons completely returning to their pre-injury level of functioning (GOSE = 8). Nevertheless, 11% experienced severe disability or had died (GOSE <5) at 6 months, 43% had mild to severe PPCS (ICD classification for PCS), and 22% had moderate to severe PPCS (ICD classification for PCS). Distributions of some predictors and outcomes differed in the CENTER-TBI compared with the development studies, particularly for models from the CRASH trial (Table S6).

Model performance in CENTER-TBI study

Models predicting GOSE. The CRASH models showed poor calibration and good discrimination for the outcome GOSE <5, which was observed in only 11% of patients. Percentage of death/unfavorable outcome was overestimated (Basic model: 20% vs. 11%, calibration intercept = -0.82; Table 4), particularly for the CT model (27% vs. 11%; calibration intercept = -1.38; Table 4). In a population with GCS 13-14; that is, the patient selection that was used in the development study, calibration-in-the-large was better (calibration intercept = -0.26 for Basic, -1.13 for CT, Table 4). The calibration slope was close to 1, indicating similar effects of predictors compared with the CRASH trial. Models showed good discriminative ability, especially the CT model (C-index = 0.79; Table 4). The discriminative ability of the CRASH models was somewhat reduced by the more homogeneous patient population of CENTER-TBI compared with the development population, as expressed by the expected C-index if the model was correct (mbc = 0.79–80 vs. C-index of 0.81–0.83 in the development data, Table 4).

The Nijmegen clinical models showed relatively good calibration, with slight underestimation of proportions of unfavorable outcome (GOSE <7; 26% vs. 28%; 22% vs. 26%; Table 4). The slopes suggested smaller effects of predictors (slope = 0.82–0.83; Table 4) and slightly worse discriminative ability in the CENTER-TBI than in the Nijmegen study (C-index = 0.66–0.69). The mbc indicated a somewhat more heterogeneous patient case-mix in the CENTER-TBI study than in the Nijmegen study (mbc = 0.72–0.70 vs. C-index 0.71–0.69; Table 4), which increased the ability to correctly discriminate between patients with GOSE <7 and those with GOSE ≥7.

For the ED+ model, calibration-in-the-large was not assessed because several predictors were not registered in CENTER-TBI. Discrimination was assessed, but it was expected to be lower because of the absence of several predictors in the CENTER-TBI data. The ability to discriminate patients with complete recovery (GOSE = 8) was lower than in the development study (C-index = 0.70; Table 4). Analyses of C-indices and slope suggested smaller
Table 3. Models for Predicting Persistent Post-Concussive Symptoms (PPCS) Validated in the CENTER-TBI Study

<table>
<thead>
<tr>
<th>Model</th>
<th>Population; Setting</th>
<th>Outcome</th>
<th>Predictors</th>
<th>Reported performance (AUC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRACK TBI Pilot, 2017</td>
<td>Adult GCS 13-15; 3 level I trauma centers, US, 2010-2012</td>
<td>Score ≥2 on 3 out of 8 symptoms (ICD) Measured by RPQ at 6 months</td>
<td>Age, Female sex, Years of education, Pre-injury migraine or headache, Pre-injury psychiatric disorders, Prior TBI, PTA, LOC</td>
<td>0.74</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UPFRONT, 2018</td>
<td>Adult GCS 13-15; sustained LOC or PTA, no substance addiction, dementia; 3 level I trauma centers, The Netherlands, 2013-2015</td>
<td>3 out of 8 symptoms (ICD) measured by HISC at 6 months</td>
<td>Female sex, Neck pain, Nausea, Headache, Post-concussive symptoms (2 weeks), Post-traumatic symptoms (2 weeks)</td>
<td>0.75&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Nijmegen, RUBICS, 2008</td>
<td>GCS 13-15; LOC &lt;30 min, 18-60 years of age; 1 level I trauma center, The Netherlands, 2004-2006</td>
<td>Score ≤2 on 13 out of 16 RPQ items at 6 months</td>
<td>Pre-injury physical health, Post-concussive symptoms (0-37 days), Post-traumatic symptoms (0-37 days)</td>
<td>0.73&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>Headache, dizziness, fatigue, irritability, sleep disturbances, poor concentration, forgetfulness, poor memory, frustration or depression<br>
<sup>b</sup>After internal validation

AUC, area under the curve; CENTER-TBI, Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury; GCS, Glasgow Coma Score; HISC, Head Injury Severity Checklist; ICD, International Classification of Diseases; LOC, loss of consciousness; PTS, post-traumatic symptoms; RPQ, Rivermead Post-Concussion Symptoms Questionnaire; RUBICS, Radboud University Brain Injury Cohort Study; TRACK-TBI, Transforming Research and Clinical Knowledge in TBI; UPFRONT,

---

Table 4. Results of External Validation of Models Predicting 6-Month Glasgow Outcome Score Extended (GOSE) in Patients with Mild Traumatic Injury (TBI): Complete Case Analyses in the CENTER-TBI Study (n=2269)

<table>
<thead>
<tr>
<th>Models for 6-month GOSE</th>
<th>Development</th>
<th>Validation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sample/ outcome events</td>
<td>Intercept (95% CI)</td>
</tr>
<tr>
<td>CRASH, Basic</td>
<td>2269/259</td>
<td>-0.82 [-0.96, -0.68]</td>
</tr>
<tr>
<td></td>
<td>558/111&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-0.26 [-0.49, -0.03]</td>
</tr>
<tr>
<td>CRASH, CT</td>
<td>2064/233</td>
<td>-1.38 [-1.53, -1.22]</td>
</tr>
<tr>
<td></td>
<td>492/93&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-1.13 [-1.39, -0.87]</td>
</tr>
<tr>
<td>Nijmegen Clinical</td>
<td>2248/635</td>
<td>0.13 [0.02, 0.23]</td>
</tr>
<tr>
<td>In all mild TBI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nijmegen Clinical</td>
<td>1098/284</td>
<td>0.24 [0.1, 0.38]</td>
</tr>
<tr>
<td>In Isolated TBI UPFRONT ED +</td>
<td>548/352&lt;sup&gt;b&lt;/sup&gt;</td>
<td>/ /</td>
</tr>
</tbody>
</table>

<sup>a</sup>Subset with Glasgow Coma Score (GCS) 13–14<br>
<sup>b</sup>Predicting positive outcome

C, concordance; CENTER-TBI, Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury; CI, confidence interval; CRASH, Corticosteroid Randomisation After Significant Head Injury; CT, computed tomography; ED, emergency department; mbc, model based concordance; UPFRONT.
Models predicting PPCS. The TRACK-TBI Pilot model correctly estimated the proportion of patients with PPCS, defined as having three or more mild to severe symptoms at 6 months (42\% vs. 42\%; Table 5), but showed overfitting (slope <0.5; Table 5) and poor discriminative ability (C-index = 0.58; Table 5). The mbc was substantially higher than the observed C-index (mbc = 0.74 vs. 0.58, Table 5) and was equivalent to the C in the development study (C = 0.74, Table 5). This pattern suggested that predictor effects (regression coefficients) differed between studies, whereas case-mix heterogeneity was comparable.

Models for prediction of PPCS, which included 2-week post-injury symptoms were validated in a smaller sample of CENTER-TBI patients, for whom that information was available, and they performed well (C-index 0.75–0.76). For the UPFRONT model, calibration-in-the-large was not assessed because of an unmeasured predictor (neck pain) in the CENTER-TBI study. The discriminability (C-index = 0.75; Table 5) and the effects of predictors were equivalent to UPFRONT (slope = 1.0; Table 5). The Nijmegen model was well calibrated, but it slightly overestimated the proportion of persons with high PPCS at 6 months (19\% vs. 15\%; Table 5). The calibration slope was close to 1, indicating similar effects of predictors. Discrimination was even slightly higher than in the development study (C-index = 0.76; Table 5) because of the somewhat more heterogeneous patient case-mix of the CENTER-TBI study compared with Nijmegen.

Calibration plots are shown in Figures S1–S7. The performance of models was consistent in analyses after imputation of missing values, except for models containing 2-week post-injury symptoms, which showed lower performance (Table S8). The sensitivity analyses with the additional inclusion criteria used in the development study showed somewhat better performance of the UPFRONT and Nijmegen models for PPCS (Table S9).

Discussion

This study identified predictors and prognostic models for 3–12 month GOSE and PPCS in persons with mild TBI, and examined the performance of five models for predicting 6-month GOSE outcome and three models for predicting 6-month PPCS in an independent data set of mild TBI patients from the CENTER-TBI study. Overall, the definitions of unfavorable outcome differed among studies, and the ability of the models to distinguish between favorable and unfavorable outcome varied substantially (C-index 0.58–0.79). The CRASH models predicting severe disability or death discriminated best, but they were poorly calibrated to the population of mild TBI patients. For prediction of PPCS, the models that included 2-week post-injury symptoms showed the best discriminative ability and were well calibrated. In models with reasonable discriminative ability, the most frequent predictors were age, GCS, and extracranial injuries for GOSE, and pre-injury health and post-injury symptoms for PPCS.

CRASH models discriminated well but they largely overestimated the percentage of persons with poor outcome, and used an end-point (GOSE <5) that might not be appropriate for the mild TBI population. It was developed for mostly moderately to severely injured patients, whereas the validation population consisted of mildly injured patients. In the previous external validation in persons with mild TBI,\(^6\) CRASH models showed good discriminative ability and miscalibration in the population with GCS 13–14, consistent with this study, but discriminated poorly in the total mild TBI population. The Nijmegen model (2008) for GOSE showed somewhat lower discriminative ability and some overfitting in our study, and low performance in the previous external validation,\(^6\) which could be partly because of the high number of candidate predictors and lack of internal validation in the model development. The performance of the UPFRONT model could not completely be assessed in the CENTER-TBI data.

The model for PPCS based on admission characteristics (TRACK-TBI, 2008) showed poor performance, consistent with the previous external validation.\(^2\) A relatively small sample size for the development of the prognostic model, a particularly effective sample size for binary outcome, might have led to unstable regression coefficients, and, consequently, differences in performance between development and validation studies.\(^2\) In addition, true differences in populations might also have contributed to the differences in the effects of predictors among studies. The performance of models containing post-injury symptoms (UPFRONT 2017, Nijmegen, 2008) were in line with their performance in the development studies. Nevertheless, the CENTER-TBI sample in which these models have been validated (both 2–3 week post-injury symptoms and 6-month PCS scores available) had lower injury severity, younger age, lower percentage of CT abnormalities, and higher GOSE than the overall mild TBI population in the CENTER-TBI study. Therefore, the performance of the models may have been different in the total mild CENTER-TBI population.

Although post-injury symptoms substantially improve prediction of outcomes, they are measured several days or weeks post-

Table 5. Results of External Validation of Models Predicting Persisting Post-Concussive Symptoms (PPCS) in Patients with Mild Traumatic Injury (TBI): Complete Case Analyses in the CENTER-TBI Study (n = 1292)

<table>
<thead>
<tr>
<th>Model for PCS</th>
<th>Development</th>
<th>Validation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C</td>
<td>Sample/Outcome events</td>
</tr>
<tr>
<td>TRACK TBI Pilot; 2017</td>
<td>0.74</td>
<td>1292/544</td>
</tr>
<tr>
<td>UPFRONT; 2018</td>
<td>0.75</td>
<td>408/147</td>
</tr>
<tr>
<td>Nijmegen; 2008*</td>
<td>0.73</td>
<td>403/61</td>
</tr>
</tbody>
</table>

*To be comparable with other models, high PCS were set as end-point instead of low PCS.

C, concordance; CENTER-TBI, Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury; CI, confidence interval; ED, emergency department; mbc, model based concordance; TRACK-TBI, Transforming Research and Clinical Knowledge in TBI; UPFRONT.
injury, which does not routinely happen across hospital centers and for all persons with mild TBI. The majority of centers only follow persons that were admitted to hospital, and frequently schedule appointments a month or later following injury, when symptoms are already persisting. The clinical applicability of a model containing predictors measured after discharge is therefore debatable for some hospital settings, and when the intention is to make predictions at the time of presentation/admission. Symptoms measured weeks after injury may be particularly helpful for making decisions about rehabilitation and specialized care. A model based on measures of medical history, injury characteristics, and early symptoms, which are easily obtainable and have shown associations with outcomes following TBI in previous studies, may be more universally useful for the early prediction of outcome. For example, protein biomarkers are currently considered to have potential for diagnosis and prediction in the context of TBI. However, their prognostic value for longer-term outcomes following mild TBI is yet to be established.

In addition to difficulties in the selection of appropriate predictors, problematic practices and lack of agreement in assessment and definition of outcomes hinder development of prognostic models for both GOSE and PPCS. The models for functional outcome used different cutoffs of GOSE to define the end-point, which could partly explain the variability in performance among them. It may be more difficult to discriminate between persons with mild TBI who have incomplete and those who have complete return to pre-injury functioning (e.g., GOSE <8) than between persons with and without disability (GOSE <7 or even GOSE <5), and different predictors may be relevant for predicting upper good overall recovery (GOSE = 8) versus disability/death (GOSE <5). In addition, using GOSE as an ordinal outcome seems to have added value over dichotomization. It is of note that the overall utility of using GOSE as an outcome measure in persons with mild TBI has been disputed, because the measure may not be sensitive enough to capture different health disturbances despite good overall functioning. Usage of a broad battery of different measures in CENTER-TBI and TRACK-TBI studies, which cover health-related generic and disease-specific quality of life, return to work and daily activities, and cognitive and psychological functioning, provide new opportunities for prognostic modeling of outcome following mild TBI. Moreover, composite measures based on several instruments, and encompassing different symptoms together with global functioning, have been proposed as an alternative to GOSE. Nevertheless, our study confirms that a significant percentage of persons with mild TBI do not return to baseline global functioning 6 months post-injury.

Similarly, there is no agreement regarding the clinical criteria or operational definition of PCS or PPCS. The Common Data Elements (CDEs) initiative, which aims to standardize data collection in TBI, recommends the RPQ for assessing post-concussive symptoms, but does not provide further guidance. For example, PCS can be mapped to ICD-10 based on several RPQ items, thereby using different scoring criteria (mild or worse and moderate or worse symptoms); composed from all RPQ items, or based on a cutoff of the total RPQ score. According to the classification methods and criteria in use, associations with predictors and other outcome measures (such as GOSE) vary substantially. In our study, models for PCS used different definitions of outcome and/or different instruments for measuring post-concussive symptoms. Therefore, a sensible and uniform definition of the PCS or PPCS end-point is a prerequisite of a good model.

A limitation of this study is that some of the predictors from validated models were not assessed in the CENTER-TBI study (e.g., early neck pain and coping styles), which prevented assessment of calibration intercepts and could have influenced other performance indices. Moreover, some predictors and outcomes were measured by different tools and instruments (e.g., medical history, psychological symptoms). The differences emphasize the importance of incorporating newly discovered predictors into the CDEs and using uniform instruments in TBI research. Additionally, the prognostic models we validated were selected based on our search strategy and eligibility criteria, and do not necessarily represent all existing prognostic models for mild TBI.

Further, a substantial percentage of CENTER-TBI patients did not have an assessment of 2–3 week post-injury symptoms and 6-month outcomes; therefore, the models that included 2–3 week symptoms were validated in a smaller and more favorable sub-sample. The response rate at 6 months was, however, in line with that in other observational studies in the field, and comparable with the response rate in the development studies. Patients with and without 6-month RPQ differed in some baseline characteristics, but without a clear pattern that would suggest a substantial systematic influence on the validation results. Further, CENTER-TBI core study included neurotrauma centers, recruitment was not consecutive, and patients without an indication for CT were not considered eligible. Therefore, the participants might not be representative of mild TBI patients in other hospital and non-hospital settings. The self-report instruments were administered in several languages and in several European countries, but the linguistic and cultural comparability was good (unpublished data). A major strength of this study is the use of a large sample of contemporary patients from different countries and numerous medical centers. In addition, all important indices relevant for external validation studies are reported.

Conclusion

We assessed the performance of several prognostic models for GOSE and PPCS. None of the models predicting GOSE have both good discriminative ability and good calibration in persons with mild TBI. Models for PPCS based on admission characteristics perform poorly, whereas models that included post-injury symptoms perform better in terms of discrimination and calibration. TBI-related and psychological symptoms collected at 2 weeks improve prediction and should be collected when possible. Novel predictors obtainable at admission, such as biomarkers, could be incorporated in future model developments. Future studies should improve prediction following mild TBI by developing models that (1) distinguish well between persons who will have longer-term negative outcomes and those who will not, (2) are calibrated to the population of mild TBI, (3) use relevant cutoffs and end-points for persons with mild TBI, such as return to normal life without TBI-related symptoms, and (4) use predictors available at admission or before discharge, which are feasible to collect in clinical practice for early detection of persons with longer-term consequences. These models could be extended with symptoms collected at 2–3 weeks for later stage outcome prediction.

Acknowledgments

The authors thank the Medical Library of the Erasmus Medical Centre for creating the literature search strategy, and Simone Dijkland and Kelly Foks for their support in data preparation.
We are grateful to all patients and investigators that participated in the CENTER-TBI study.

**The CENTER-TBI Participants and Investigators**

Cecilia Åkerlund, Karolinska Institutet, Stockholm, Sweden; Kristzina Amrein, University of Pécs, Pécs, Hungary; Nada Andelic, Oslo University Hospital and University of Oslo, Oslo, Norway; Lasse Andreassen, University Hospital Northern Norway, Tromso, Norway; Audny Anke, University Hospital Northern Norway, Tromso, Norway; Anna Antoni, Medical University Vienna, Vienna, Austria; Gérard Audibert, University Hospital Nancy, Nancy, France; University Hospital Nancy, Nancy, France; Philippe Azouvi, Raymond Poincare Hospital, Assistance Publique – Hopitaux de Paris, Paris, France; Maria Luisa Azzolini, S. Raffaele University Hospital, Milan, Italy; Ronald Bartels, Radboud University Medical Center, Nijmegen, The Netherlands; Pal Barzó, University of Szeged, Szeged, Hungary; Romuald Beaunais, ARTTIC, Munchen, Germany; Ronny Beer, Medical University Innsbruck, Innsbruck, Austria; Bo-Michael Bellander, Karolinska University Hospital, Stockholm, Sweden; Antonio Belli, NIHR Surgical Reconstruction and Microbiology Research Centre, Birmingham, UK; Habib Benali, Assistance Publique – Hopitaux de Paris, Paris, France; Maurizio Berardino, AOI Città della Salute e della Scienza di Torino - Orthopedic and Trauma Center, Turin, Italy; Luigi Beretta, S. Raffaele University Hospital, Milan, Italy; Morten Blaabjerg, Odense University Hospital, Odense, Denmark; Peter Bragge, Monash University, Victoria, Australia; Alexandra Brazinova, Trnava University, Trnava, Slovakia; Vibeke Brinck, Quesgen Systems Inc., Burlingame, California, USA; Joanne Brooker, Monash University, Melbourne, Australia; Camilla Brorsson, Umeå University, Umeå, Sweden; Anders Buki, University of Pécs, Hungary; Monika Bullinger, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Manuel Cabeleira, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK; Alessio Caccioppola, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; Emiliania Calappi, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; Maria Rosa Calvi, S. Raffaele University Hospital, Milan, Italy; Peter Cameron, Monash University, Melbourne, Victoria, Australia; Guillermo Carbayo Lozano, Hospital of Crues, Bilbao, Spain; Marco Carbonara, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; Ana M. Castaño-León, Hospital Universitario 12 de Octubre, Madrid, Spain; Simona Cavallo, AOI Città della Salute e della Scienza di Torino - Orthopedic and Trauma Center, Turin, Italy; Giorgio Chevallard, Niguarda Hospital, Milan, Italy; Arturo Chieregato, Niguarda Hospital, Milan, Italy; Giuseppe Citeri, Università Milano Bicocca, Milano, Italy and ASST di Monza, Monza, Italy; Iris Ceyisakar, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands; Hans Clusmann, Aachen University, Aachen, Germany; Mark Coburn, University Hospital of Aachen, Aachen, Germany; Jonathan Coles, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK; Jamie D. Cooper, Monash University and The Alfred Hospital, Melbourne, Victoria, Australia; Marta Correia, MRC Cognition and Brain Sciences Unit, Cambridge, UK; Amra Cvijic, Universitätspital Göttingen, Göttingen, Germany; Nicola Curry, Oxford University Hospitals NHS Trust, Oxford, UK; Endre Czeiter, University of Pécs, Hungary; Marek Czonsyka, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK; Claire Dahyot-Fizelier, CHU Pitié Salpêtrière, Paris, France; Paul Dark, Salford Royal Hospital NHS Foundation Trust, Salford, UK; Helen Dawes, Oxford Brookes University, Oxford, UK; Véronique De Keyser, Antwerp University Hospital and University of Antwerp, Edegem, Belgium; Vincent Degos, Assistance Publique – Hopitaux de Paris, Paris, France; Francesco Della Corte, Maggiore Della Carità Hospital, Novara, Italy; Hugo den Boogert, Radboud University Medical Center, Nijmegen, The Netherlands; Bart Depreitere, University Hospitals Leuven, Leuven, Belgium; Dula Dilvesi, University of Novi Sad, Novi Sad, Serbia; Abhishek Dixit, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK; Emma Donoghue, Monash University, Melbourne, Australia; Jens Dreier, Charité – Universitätsmedizin Berlin, Berlin, Germany; Guy-Loup Dulière, CHR Citadelle, Liège, Belgium; Ari Ercole, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK; Patrick Esser, Oxford Brookes University, Oxford, UK; Erzsébet Ezer, University of Pécs, Pécs, Hungary; Martin Fabricius, Region Hovedstaden Righospitalet, Copenhagen, Denmark; Valery L. Feigin, Auckland University of Technology, Auckland, New Zealand; Kelly Foks, Erasmus MC, Rotterdam, the Netherlands; Shirin Frisvold, University Hospital Northern Norway, Tromso, Norway; Alex Furmanov, Hadasah-Hebrew University Medical Center, Jerusalem, Israel; Pablo Gagliardo, Fundación Investigando de Neurorehabilitación (FIVAN), Valencia, Spain; Damien Galanaud, Assistance Publique – Hopitaux de Paris, Paris, France; Dashiell Gantner, Monash University, Melbourne, Victoria, Australia; Guoyi Gao, Shanghai Renji Hospital, Shanghai Jiaotong University/School of Medicine, Shanghai, China; Prdeep George, Karolinska Institutet, Stockholm, Sweden; Alexandre Ghysen, CHU, Liège, Belgium; Ledle Giga, Pauls Stradins Clinical University Hospital, Riga, Latvia; Ben Glocker, Imperial College London, London, UK; Jagoš Golubovic, University of Novi Sad, Novi Sad, Serbia; Pedro A. Gomez, Hospital Universitario 12 de Octubre, Madrid, Spain; Johannes Gratz, Medical University of Vienna, Austria; Benjamin Gravesteijn, Erasmus Medical Center Medical Center, Rotterdam, The Netherlands; Francesca Grossi, Maggiore Della Carità Hospital, Novara, Italy; Russell L. Gruen, Medical University of Vienna, Austria; Deepak Gupta, All India Institute of Medical Sciences, New Delhi, India; Juanita A. Haagsma, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands; Iain Haitsma, Erasmus MC, Rotterdam, The Netherlands; Raimund Helbok, Medical University of Innsbruck, Innsbruck, Austria; Eirik Helseth, Oslo University Hospital Oslo, Norway; Lindsay Horton, University of Stirling, Stirling, UK; Jilske Huijben, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands; Peter J. Hutchinson, Addenbrooke’s Hospital and University of Cambridge, Cambridge, UK; Bram Jacobs, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Stefan Jankowski, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; Mike Jarrett, Quesgen Systems Inc., Burlingame, California, USA; Ji-yao Jiang, Shanghai Renji Hospital, Shanghai Jiaotong University/School of Medicine, Shanghai, China; Faye Johnson, Salford Royal Hospital NHS Foundation Trust, Salford, UK; Kelly Jones, Auckland University of Technology, Auckland, New Zealand; Milad Karan, University of Novi Sad, Novi Sad, Serbia; Angelos G. Kolias, Addenbrooke’s Hospital and University of Cambridge, Cambridge, UK; Erwin Kompane, Erasmus Medical Center, Rotterdam, The Netherlands; Daniel Kondziella, Region Hovedstaden Righospitalet, Copenhagen, Denmark; Evgenios Koraropoulos, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK; Lars-Owe Koskinen, Umeå University, Umeå, Sweden; Noémi Kovács, University of Pécs, Pécs, Hungary; Ana
Kowark, University Hospital of Aachen, Aachen, Germany; Alfonso Lagares, University Hospitalario 12 de Octubre, Madrid, Spain; Linda Lanyon, Karolinska Institutet, Stockholm, Sweden; Steven Laureys, University of Liège, Liège, Belgium; Fiona Lecky, University of Sheffield, Sheffield, UK; and Salford Royal Hospital, Salford UK; Didier Ledoux, University of Liège, Liège, Belgium; Rolf Lefering, Witten/Herdecke University, Cologne, Germany; Valerie Legrand, ICON, Paris, France; Aurelie Lejeune, Lille University Hospital, Lille, France; Leon Levi, Rambam Medical Center, Haifa, Israel; Roger Lightfoot, University Hospitals Southampton NHS Trust, Southampton, UK; Hester Lingsma, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands; Andrew I.R. Maas, Antwerp University Hospital and University of Antwerp, Edegem, Belgium; Marc Maegel, Cologne-Merheim Medical Center (CMMC), Witten/Herdecke University, Cologne, Germany; Marek Majdan, Trnava University, Trnava, Slovakia; Alex Manara, Southmead Hospital, Bristol, Bristol, UK; Geoffrey Manley, University of California, San Francisco, California, USA; Costanza Martino, M. Bufalini Hospital, Cesena, Italy; Hugues Marechal, CHR Citadelle, Liège, Belgium; Julia Mattern, University Hospital Heidelberg, Heidelberg, Germany; Catherine McMahon, The Walton Centre NHS Foundation Trust, Liverpool, UK; Béla Melegh, University of Pécs, Pécs, Hungary; David Menon, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK; Tomas Menovsky, Antwerp University Hospital and University of Antwerp, Edegem, Belgium; Ana Mikolic, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands; Benoît Misset, University of Liège, Liège, Belgium; Visakh Muraleedharan, Karolinska Institutet, Stockholm, Sweden; Lynnette Murray, Monash University, Melbourne, Victoria, Australia; Ancuta Negrut, Emergency County Hospital Timisoara, Timisoara, Romania; David Nelson, Karolinska Institutet, Stockholm, Sweden; Virginia Newcombe, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK; Daan Nieboer, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands; József Nyírádi, University of Pécs, Pécs, Hungary; Otetsile Olubukola, University of Sheffield, Sheffield, UK; Matej Orešic, Ōrebro University, Ōrebro, Sweden; Fabrizio Ortolano, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; Aarno Palotie, University of Helsinki, Helsinki, Finland; Scandinavia; Malin Persson, University Hospital and University of Turku, Turku, Finland; Viktória Tamás, University of Pécs, Pécs, Hungary; Tomas Tamosuitis, Klinik für Neurochirurgie, Klinikum Ludwigshafen, Ludwigshafen, Germany; Samuel Rocka, Kaunas University of Health Sciences, Kaunas, Lithuania; Mark Steven Taylor, Trnava University, Trnava, Slovakia; Braden Te Ao, Auckland University of Technology, Auckland, New Zealand; Olli Tenovuo, Turku University, Turku, Finland; Alice Theadom, Auckland University of Technology, Auckland, New Zealand; Matt Thomas, Southmead Hospital, Bristol, Bristol, UK; Dick Tibboel, Erasmus Medical Center, Sophia Children’s Hospital, Rotterdam, The Netherlands; Marjolein Timmers, Erasmus Medical Center, Rotterdam, The Netherlands; Christos Tolias, Central Hospital; Malin Rambadagalla, Rezekne Hospital, Latvia; Jonathan Rhodes, NHS Lothian and University of Edinburgh, Edinburgh, UK; Sylvia Richardson, Cambridge Institute of Public Health, Cambridge, UK; Sophie Richter, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK; Samuli Ripatti, University of Helsinki, Helsinki, Finland; Saulius Rocka, Kaunas University of Technology and Vilnius University, Vilnius, Lithuania; Cecília Roe, Oslo University Hospital/University of Oslo, Oslo, Norway; Olav Roise, Oslo University Hospital, Oslo, Norway; Jonathan Rosand, The Broad Institute, Cambridge MA Harvard Medical School and Massachusetts General Hospital, Boston MA, USA; Jeffrey V. Rosenfeld, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia; Christina Rosenlund, Odense University Hospital, Odense, Denmark; Guy Rosenthal, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rolf Rossaint, University Hospital of Aachen, Aachen, Germany; Sandra Rossi, Azienda Ospedaliera Università di Padova, Padova, Italy; Daniel Rueckert, Imperial College London, London, UK; Martin Rusnák, International Neurotrauma Research Organisation, Vienna, Austria; Juan Sahauquillo, Vall d’Hebron Research Institute, Barcelona, Spain; Oliver Sakowitz, University Hospital Heidelberg, Heidelberg, Germany and Klinik für Neurochirurgie, Klinikum Ludwigshafen, Ludwigshafen, Germany; Renan Sanchez-Porras, Klinik für Neurochirurgie, Klinikum Ludwigshafen, Ludwigshafen, Germany; Janos Sandor, University of Debrecen, Debrecen, Hungary; Nadine Schäfer, Witten/Herdecke University, Cologne, Germany; Silke Schmidt, University Greifswald, Greifswald, Germany; Herbert Schoechl, AUA Trauma Hospital, Salzburg, Austria; Guus Schoonman, Elisabeth-Twee Steden Ziekenhuis, Tilburg, The Netherlands; Rico Frederik Schou, Odense University Hospital, Odense, Denmark; Elisabeth Schwendewein, Medical University Vienna, Vienna, Austria; Charlie Sewalt, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands; Toril Skandsen, Norwegian University of Science and Technology, NTNU and St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; Peter Smielewski, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK; Abayomi Sorinola, University of Pécs, Pécs, Hungary; Emmanuel Stamatakis, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK; Simon Stanworth, Oxford University Hospitals NHS Trust, Oxford, UK; Robert Stevens, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; William Stewart, Queen Elizabeth University Hospital and University of Glasgow, Glasgow, UK; Ewout W. Steyerberg, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands and Leiden University Medical Center, Leiden, The Netherlands; Nino Stocchi, Milan University, and Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; Aarno Palotie, University of Helsinki, Helsinki, Finland; Scandinavia; Malin Persson, University Hospital and University of Turku, Turku, Finland; Viktória Tamás, University of Pécs, Pécs, Hungary; Tomas Tamosuitis, Kaunas University of Health Sciences, Kaunas, Lithuania; Mark Steven Taylor, Trnava University, Trnava, Slovakia; Braden Te Ao, Auckland University of Technology, Auckland, New Zealand; Olli Tenovuo, Turku University, Turku, Finland; Alice Theadom, Auckland University of Technology, Auckland, New Zealand; Matt Thomas, Southmead Hospital, Bristol, Bristol, UK; Dick Tibboel, Erasmus Medical Center, Sophia Children’s Hospital, Rotterdam, The Netherlands; Marjolein Timmers, Erasmus Medical Center, Rotterdam, The Netherlands; Christos Tolias,
Kings College London, London, UK; Tony Trapani, Monash University, Melbourne, Victoria, Australia; Cristina Maria Tudora, Emergency County Hospital Timisoara, Timisoara, Romania; Peter Vajkoczy, Charité – Universitätsmedizin Berlin, Berlin, Germany; Shirley Vallance, Monash University, Melbourne, Victoria, Australia; Egils Valeinis, Pauls Stradins Clinical University Hospital, Riga, Latvia; Zoltán Vámos, University of Pécs, Pécs, Hungary; Mathieu van der Jagt, Erasmus MC – University Medical Center Rotterdam, Rotterdam, The Netherlands; Gregory Van der Steen, Antwerp University Hospital and University of Antwerp, Edegem, Belgium; Joukje van der Naalt, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Jeroen T.J.M. van Dijck, Leiden University Medical Center, Leiden, The Netherlands and Medical Center Haaglanden, The Hague, The Netherlands; Thomas A. van Essen, Leiden University Medical Center, Leiden, The Netherlands and Medical Center Haaglanden, The Hague, The Netherlands; Wim Van Hecke, icometrix NV, Leuven, Belgium; Caroline van Heugten, Oxford Brookes University, Oxford, UK; Dominique Van Praag, Antwerp University Hospital, Edegem, Belgium; Thijs Vande Veyere, icometrix NV, Leuven, Belgium; Roel P.J. van Wijk, Leiden University Medical Center, Leiden, The Netherlands and Medical Center Haaglanden, The Hague, The Netherlands; Alessia Vargiolu, ASST di Monza, Monza, Italy; Emmanuel Vega, Lille University Hospital, Lille, France; Kimberley Velt, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands; Jan Verheyden, icometrix NV, Leuven, Belgium; Paul M. Vespa, University of California, Los Angeles, Los Angeles, California, USA; Anne Vik, Norwegian University of Science and Technology, NTNU, Trondheim, Norway and St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; Rimantas Vilkinis, Kaunas University of Health Sciences, Kaunas, Lithuania; Victor Volovoci, Erasmus MC, Rotterdam, The Netherlands; Nicole von Steinbüchel, Universitätmedizin Göttingen, Göttingen, Germany; Daphne Voormolen, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands; Petar Vulevski, University of Novi Sad, Novi Sad, Serbia; Kevin K.W. Wang, University of Florida, Gainesville, Florida, USA; Eveline Wiegers, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands; Guy Williams, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK; Lindsay Wilson, University of Stirling, Stirling, UK; Stefan Winzeck, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK; Stefan Wolf, Charité – Universitätsmedizin Berlin, Berlin, Germany; Zhihui Yang, University of Florida, Gainesville, Florida, USA; Peter Ylén, VTT Technical Research Centre, Tampere, Finland; Alexander Younisi, University Hospital Heidelberg, Heidelberg, Germany; Frederick A. Zeiler, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK and University of Manitoba, Winnipeg, MB, Canada; Veronika Zelinkova, Trnava University, Trnava, Slovakia; Agate Ziverte, Pauls Stradins Clinical University Hospital, Riga, Latvia; and Tommaso Zorerle, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.

Ethical Approval

The CENTER-TBI study (EC grant 602150) has been conducted in accordance with all relevant laws of the European Union if directly applicable or of direct effect and all relevant laws of the country where the recruiting sites were located, including but not limited to, the relevant privacy and data protection laws and regulations (the “Privacy Law”), the relevant laws and regulations on the use of human materials, and all relevant guidance relating to clinical studies from time to time in force including, but not limited to, the ICH Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) (“ICH GCP”) and the World Medical Association Declaration of Helsinki entitled “Ethical Principles for Medical Research Involving Human Subjects”. Informed consent by the patients and/or the legal representative/next of kin was obtained, according to the local legislations, for all patients recruited in the core data set of CENTER-TBI and documented in the electronic case report form (e-CRF). Ethical approval was obtained for each recruiting site. The list of sites, ethical committees, approval numbers, and approval dates can be found on the Web site https://www.centerptbi.eu/project/ethical-approval

Funding Information

The authors Mikolić, Polinder, Steyerberg, Retel Helmrich, Maas, Voormolen, Steinbuechel, Wilson, and Lingsma were supported by the European Union 7th Framework programme (EC grant 602150). Additional support was obtained from the Hannelore Kohl Stiftung (Germany), OneMind (USA), Integra LifeSciences Corporation (USA), and Neurotrauma Sciences (USA).

Author Disclosure Statement

No competing financial interests exist.

Supplementary Material

Supplementary Table S1
Supplementary Table S2
Supplementary Table S3
Supplementary Table S4
Supplementary Table S5
Supplementary Table S6
Supplementary Table S7
Supplementary Table S8
Supplementary Table S9

References


Address correspondence to: Ana Mikolic’, MSc
Erasmus MC-University Medical Center Rotterdam
Department of Public Health
PO Box 2040
3000 CA Rotterdam
The Netherlands
E-mail: a.mikolic@erasmusmc.nl